Patents by Inventor Ruiliang Lu

Ruiliang Lu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PROCESS FOR MAKING SARECYCLINE HYDROCHLORIDE
    Publication number: 20210017123
    Abstract: The described invention relates to sarecycline, related compounds, intermediates and salts thereof and processes for preparing the same.
    Type: Application
    Filed: April 5, 2019
    Publication date: January 21, 2021
    Inventors: Giovanni PALOMBI, Eugenio CASTELLI, Giuseppe MOTTA, Meinrad BRENNER, Ruiliang LU, Shaozhi HUANG, William Paul ARMSTRONG, Gajanan JOSHI, Farzaneh SEYEDI, Sean JOHNSTON
  • Antibacterial GG peptides and methods of use
    Patent number: 8431528
    Abstract: The present invention provides antibacterial peptides isolated from lactobacillus GG. Also provided are methods of treating an individual having a bacterial infection or at risk for developing a bacterial infection, comprising the steps of administering an antibacterial peptide of the invention to an individual having a bacterial infection or at risk for developing a bacterial infection.
    Type: Grant
    Filed: May 15, 2009
    Date of Patent: April 30, 2013
    Assignee: University of Maryland, Baltimore
    Inventors: Ruiliang Lu, Alessio Fasano
  • Antibacterial lactobacillus GG peptides and methods of use
    Publication number: 20110105385
    Abstract: The present invention provides antibacterial peptides isolated from lactobacillus GG. Also provided are methods of treating an individual having a bacterial infection or at risk for developing a bacterial infection, comprising the steps of administering an antibacterial peptide of the invention to an individual having a bacterial infection or at risk for developing a bacterial infection.
    Type: Application
    Filed: May 15, 2009
    Publication date: May 5, 2011
    Inventors: Ruiliang Lu, Alessio Fasano
  • Methods for screening for modulators of CXCR3 signaling
    Patent number: 7622264
    Abstract: CXCR3 is identified as a physiological receptor for Gliadin. Assays for determining modulators of CXCR3 signaling are provided. Fragments of gliadin which function as inhibitors of CXCR3 signaling can be determined. Methods for treating diseases relating to gluten and/or autoimmunity by targeting CXCR3 are provided. Such diseases include celiac disease, gluten sensitivity, gluten allergy, rheumatoid arthritis, multiple sclerosis, immune-mediated or type 1 diabetes mellitus, inflammatory bowel diseases, systemic lupus erythematosus, psoriasis, scleroderma, and autoimmune thyroid diseases.
    Type: Grant
    Filed: February 16, 2006
    Date of Patent: November 24, 2009
    Assignee: University of Maryland, Baltimore
    Inventors: Alessio Fasano, Ruiliang Lu, Stefanie N. Vogel, Julie Brownley, Karen Lammers
  • CXCR3 is a gliadin receptor
    Publication number: 20070048801
    Abstract: Gliadin is identified as a physiological receptor for CXCR3. Assays for determining modulators of CXCR3 signaling are provided. Fragments of gliadin which function as inhibitors of CXCR3 signaling can be determined. Methods for treating diseases relating to gluten and/or autoimmunity by targeting CXCR3 are provided. Such diseases include celiac disease, gluten sensitivity, gluten allergy, rheumatoid arthritis, multiple sclerosis, immune-mediated or type 1 diabetes mellitus, inflammatory bowel diseases, systemic lupus erythematosus, psoriasis, scleroderma, and autoimmune thyroid diseases.
    Type: Application
    Filed: February 16, 2006
    Publication date: March 1, 2007
    Applicant: University of Maryland, Baltimore
    Inventors: Alessio Fasano, Ruiliang Lu, Stefanie Vogel, Julie Brownley, Karen Lammers
  • Method of using Zot to inhibit lymphocyte proliferation in an antigen-specific manner
    Patent number: 6733762
    Abstract: Methods of using Zot or zonulin as an antigen specific inhibitor of APC activity and lymphocyte proliferation, being primarily useful in the field of immunoregulation and immunotherapy as described. Specifically, Zot and zonulin inhibit antigen presenting cell-mediated antigen-specific lymphocyte proliferation in a dose dependent manner. This effect is associated with the presence of a macrophage surface receptor to which Zot binds in a specific and saturable way. This down-regulation of the immune response is, at least in part, associated with a decreased uptake of antigen.
    Type: Grant
    Filed: May 3, 2001
    Date of Patent: May 11, 2004
    Assignee: University of Maryland, Baltimore
    Inventors: Alessio Fasano, Marcelo B. Sztein, Ruiliang Lu, Michael K. Tanner